Literature DB >> 8580223

Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.

S K Schultz1, D D Miller, S Arndt, S Ziebell, S Gupta, N C Andreasen.   

Abstract

We examined whether patients exhibiting withdrawal-emergent dyskinesia (WE-D) represent a group vulnerable to subsequent development of tardive dyskinesia (TD). WE-D was defined as moderate abnormal movements during antipsychotic withdrawal in persons without persistent TD. We assessed patients with schizophrenia-spectrum illness participating in withdrawal from antipsychotic medication. Patients with WE-D were compared to those without dyskinesia and to those with persistent TD. Clinical measures included duration of illness and antipsychotic exposure, negative symptoms, and neurologic soft signs. We hypothesized that WE-D patients would not differ from persistent-TD patients across the above variables, but would differ from non-TD patients. Patients without TD significantly differed from persistent TD in duration of illness, medication exposure and neurologic soft signs. WE-D did not differ from TD across these measures. No-TD patients also showed less duration of medication exposure and neurologic soft signs than those with WE-D.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8580223     DOI: 10.1016/0006-3223(95)00082-8

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

Review 1.  Oxidative mechanisms and tardive dyskinesia.

Authors:  James B Lohr; Ronald Kuczenski; Alexander B Niculescu
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

Authors:  Mark Abie Horowitz; Sameer Jauhar; Sridhar Natesan; Robin M Murray; David Taylor
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 7.348

Review 3.  Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Authors:  Hanna Bergman; John Rathbone; Vivek Agarwal; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

4.  Amisulpride withdrawal dyskinesia: a case report.

Authors:  Yu-Chi Lo; Ying-Chieh Peng
Journal:  Ann Gen Psychiatry       Date:  2017-06-14       Impact factor: 3.455

Review 5.  Movement disorders in psychiatric patients.

Authors:  Laura Perju-Dumbrava; Peter Kempster
Journal:  BMJ Neurol Open       Date:  2020-12-01

Review 6.  Treatable Hyperkinetic Movement Disorders Not to Be Missed.

Authors:  Aurélie Méneret; Béatrice Garcin; Solène Frismand; Annie Lannuzel; Louise-Laure Mariani; Emmanuel Roze
Journal:  Front Neurol       Date:  2021-12-01       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.